PACB vs CTKB
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PACB · Pacific Biosciences of California$1.63 ▼ 7.39%
CTKB · Cytek Biosciences$6.12 ▼ 3.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PACB -34.8%
- CTKB +4.8%
Head to head
| Metric | PACB | CTKB |
|---|---|---|
| Price | $1.63 | $6.12 |
| Change today | ▼ 7.39% | ▼ 3.16% |
| Market cap | $510.07M | $800.40M |
| Return, 3 months | +27.3% | +37.8% |
| Return, year to date | -12.8% | +21.2% |
| Return, 1 year | -26.6% | +4.1% |
| P/E (TTM) | – | – |
| P/B | -8.3 | 2.5 |
| P/E percentile vs own 5y | 47th | 70th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +5.5% | +1.8% |
| Net profit growth (YoY) | +0.4% | -11.3% |
| Gross margin | 34.4% | 54.7% |
| Operating margin | -100.1% | -21.1% |
| Net margin | -81.3% | -39.1% |
| Return on equity | – | -23.2% |
| Analyst target vs. price | +62.0% | +18.5% |
| Analyst buy share | 40% | 100% |
| RSI (14) | 35 | 57 |
| 30-day volatility | 107.0% | 58.9% |
| Max drawdown, 1 year | -58.4% | -42.9% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CTKB is the largest of the group by market value.
- CTKB has returned the most over the past year.
- PACB is growing revenue fastest.
- CTKB keeps the most profit per dollar of sales.
- CTKB has been the calmest stock over the last 30 days.